Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRE-1: Bococizumab in High Risk Cardiovascular Subjects
NCT01975376Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 36
01
Overview
A Phase 3 trial of bococizumab in cardiovascular disease (CVD), sponsored by Pfizer. Started Oct 2013; status: terminated.
02
Drugs
bococizumab
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT01975376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01975376.